MedPath

Radiprodil

Generic Name
Radiprodil
Drug Type
Small Molecule
Chemical Formula
C21H20FN3O4
CAS Number
496054-87-6
Unique Ingredient Identifier
5XGC17ZKUF

Overview

Radiprodil has been used in trials studying the treatment of Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Jun 13, 2025

Radiprodil (DB12260): A Comprehensive Report on its Pharmacology, Clinical Development, and Therapeutic Potential

1. Introduction to Radiprodil

1.1. Overview

Radiprodil is an investigational small molecule drug that has been evaluated for a range of neurological conditions. Its development journey has seen a strategic evolution, moving from broader applications to a more focused approach targeting rare, severe neurodevelopmental disorders where its specific mechanism of action is most relevant.[1] Initially explored for conditions such as Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain (DPNP), radiprodil is currently under active clinical development primarily for GRIN-related Neurodevelopmental Disorders (GRIN-NDD), Tuberous Sclerosis Complex (TSC), and Focal Cortical Dysplasia (FCD) Type II. This shift underscores a trend towards precision medicine, leveraging a deeper understanding of the drug's molecular interactions and the pathophysiology of specific diseases.

The development pathway of radiprodil highlights the complexities and iterative nature of pharmaceutical research. Early setbacks in demonstrating efficacy for more common conditions have not led to its abandonment but rather to a refined strategy. This redirection is based on emerging clinical data and a clearer understanding of how radiprodil's unique pharmacological profile can address the underlying mechanisms of specific, often genetically defined, patient populations.

1.2. Key Identifiers and Properties

Radiprodil is characterized by several key identifiers and properties that define its nature and therapeutic focus:

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.